Page 62 - Merck Sharp News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

IO Biotech Announces Second Quarter Results for 2022 • ... | August 11, 2022

Starpharma (ASX:SPL) has signed a new DEP research agreement with MSD, the trade name of Merck Sharp & Dohme.

/PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp...

Investegate announcements from Evaxion Biotech, Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

Melbourne, Australia; 10 August 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has signed a new DEP ® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP ® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021.

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for melanomaAnnounced gonorrhea as second bacterial product

Adding neoadjuvant nivolumab to chemotherapy in stage IIIA/IIIB non¬–small cell lung cancer markedly improves both progression-free and overall survival over neoadjuvant chemotherapy alone.

08.08.2022 - Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology meetingPromising pre-clinical data on universal flu vaccine ...

Many clinical trials supporting cancer drug approvals are ineligible for individual participant data sharing, a new study suggests.